SARTORIUS is trading at 36.40 as of the 18th of January 2025. This is a 0.55% down since the beginning of the trading day. The stock's lowest day price was 36.4. SARTORIUS has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of November 2024 and ending today, the 18th of January 2025. Click here to learn more.
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company was founded in 1870 and is headquartered in Gttingen, Germany. SARTORIUS operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. The company has 342.08 M outstanding shares. More on SARTORIUS AG UNSPADR
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. SARTORIUS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding SARTORIUS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
SARTORIUS AG UNSPADR (SRT4) is traded on Frankfurt Exchange in Germany and employs 15,942 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 27.76 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SARTORIUS's market, we take the total number of its shares issued and multiply it by SARTORIUS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. SARTORIUS AG UNSPADR operates under Healthcare sector and is part of Medical Instruments & Supplies industry. The entity has 342.08 M outstanding shares.
SARTORIUS AG UNSPADR has accumulated about 446.8 M in cash with 736.83 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.53.
Check SARTORIUS Probability Of Bankruptcy
SARTORIUS AG UNSPADR Risk Profiles
Although SARTORIUS's alpha and beta are two of the key measurements used to evaluate SARTORIUS's performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in SARTORIUS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio Optimization Now
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
SARTORIUS financial ratios help investors to determine whether SARTORIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SARTORIUS with respect to the benefits of owning SARTORIUS security.